The presentations will highlight preclinical research evaluating GLIX1 across multiple glioblastoma models, as well as the design of the ongoing Phase 1/2a clinical trial evaluating GLIX1 in patients with recurrent or progressive high-grade glioma and other solid tumors.

Presentation Details:

Title: GLIX1, a TET2 activator targeting DNA damage response: potent anti-tumor activity across multiple glioblastoma models; orthotopic CDX models and a subcutaneous TMZ-resistant PDX model

Presenter: Dr. Adam Robertson, Ph.D., Chief Scientific Officer, Hemispherian AS

Abstract code: EXTH-31

Format: Poster presentation

Date/time: Friday, November 13, 2026, 7:30-9:30 p.m. EST

Location: Pennsylvania Convention Center, Exhibit Halls D and E

Title: Phase 1/2a study of GLIX1, a novel first-in-class oral TET2 activator, for the treatment of recurrent or progressive high-grade glioma

Presenter: Ditte Primdahl, MD, Northwestern University Feinberg School of Medicine

Abstract code: CTNI-25

Format: Poster presentation

Date/time: Friday, November 13, 2026, 7:30-9:30 p.m. EST

Location: Pennsylvania Convention Center, Exhibit Halls D and E

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.